Abstract CT016: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors
Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), D. Voliotis(Bayer (United States)), Lukas Makris(DM-STAT (United States)), Philippe Pultar(Department of Pharmaceuticals), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Hirva Mamdani(Wayne State University), Pavani Chalasani(University of Arizona), Mihaela Gazdoiu(Novartis (Switzerland))
Cited by 24
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530